Hans H Kreipe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7519811/publications.pdf

Version: 2024-02-01

115	3,719	29 h-index	57
papers	citations		g-index
119	119	119	5871 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression—a potential differential diagnostic pitfall between PTLD and PTSMT. Annals of Hematology, 2022, 101, 881-883.	0.8	1
2	Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. Cancer Research, 2022, 82, PD10-11-PD10-11.	0.4	3
3	Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. Cancer Research, 2022, 82, P2-13-03-P2-13-03.	0.4	O
4	Evolution of severe (transfusionâ€dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophageâ€associated failure of the eythropoietic niche. British Journal of Haematology, 2022, , .	1.2	3
5	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	1.3	19
6	Donorâ€transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. British Journal of Haematology, 2022, , .	1.2	1
7	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2557-2567.	0.8	49
8	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	2.9	18
9	ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Modern Pathology, 2022, 35, 1804-1811.	2.9	4
10	Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell, 2021, 28, 637-652.e8.	5.2	92
11	A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia, 2021, 35, 1763-1772.	3.3	9
12	Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis. Clinical Epigenetics, 2021, 13, 28.	1.8	1
13	Transcription factor <scp>AP</scp> â€⊋beta in development, differentiation and tumorigenesis. International Journal of Cancer, 2021, 149, 1221-1227.	2.3	16
14	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers, 2021, 13, 3695.	1.7	35
15	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819.	3.0	319
16	Chromosome 2q gain and epigenetic silencing of <scp>GATA3</scp> in microglandular adenosis of the breast. Journal of Pathology: Clinical Research, 2021, 7, 220-232.	1.3	3
17	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Medicine, 2021, 10, 8581-8594.	1.3	14
18	Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia, 2020, 34, 1364-1372.	3.3	27

#	Article	IF	Citations
19	Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer. Cancer, 2020, 126, 4847-4858.	2.0	33
20	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood, 2020, 136, 2051-2064.	0.6	56
21	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Modern Pathology, 2020, 33, 2483-2498.	2.9	26
22	Feasibility of Combined Detection of Gene Mutations and Fusion Transcripts in Bone Marrow Trephines from Leukemic Neoplasms. Journal of Molecular Diagnostics, 2020, 22, 591-598.	1.2	2
23	Clinically latent and autopsy-verified inflammatory disorders and malignant tumours in transplant patients. Journal of Clinical Pathology, 2020, , jclinpath-2020-207080.	1.0	1
24	Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. Annals of Hematology, 2019, 98, 515-517.	0.8	2
25	Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification. Pathology Research and Practice, 2019, 215, 152611.	1.0	2
26	Comparison of clinical diagnoses and autopsy findings in 54 cases with lymphoid neoplasms. Journal of Hematopathology, 2019, 12, 67-74.	0.2	1
27	LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype. PLoS ONE, 2019, 14, e0216374.	1.1	12
28	Complement receptor-associated CD163+/CD18+/CD11c+/CD206-/CD209- expression profile in chronic histiocytic intervillositis of the placenta. Placenta, 2019, 78, 23-28.	0.7	10
29	Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661989491.	1.0	5
30	Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Medicine, 2019, 8, 742-750.	1.3	19
31	<i>ERBB2</i> mutation frequency in lobular breast cancer with pleomorphic histology or highâ€risk characteristics by molecular expression profiling. Genes Chromosomes and Cancer, 2019, 58, 175-185.	1.5	27
32	Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level. Blood, 2019, 134, 1675-1675.	0.6	2
33	Molecular profile of inflammatory and megakaryocytic factors in pediatric myelodysplastic syndrome with acute myelofibrosis. Pediatric Blood and Cancer, 2018, 65, e27048.	0.8	2
34	<i>CDKN2A</i> loss and <i>PIK3CA</i> mutation in myoepithelialâ€like metaplastic breast cancer. Journal of Pathology, 2018, 245, 373-383.	2.1	28
35	Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 1055-1059.	1.4	14
36	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β. Laboratory Investigation, 2018, 98, 117-129.	1.7	24

#	Article	IF	Citations
37	Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. Modern Pathology, 2018, 31, 56-61.	2.9	29
38	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. International Journal of Molecular Sciences, 2018, 19, 3269.	1.8	8
39	Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis. Annals of Hematology, 2018, 97, 2099-2106.	0.8	10
40	Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 577-582.	1.4	14
41	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	3.3	86
42	Image analysis of immune cell patterns in the human mammary gland during the menstrual cycle refines lymphocytic lobulitis. Breast Cancer Research and Treatment, 2017, 164, 305-315.	1.1	3
43	Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation. Annals of Hematology, 2017, 96, 1403-1405.	0.8	3
44	Macrophage density in early surveillance biopsies predicts future renal transplant function. Kidney International, 2017, 92, 479-489.	2.6	53
45	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	1.4	29
46	Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice. Journal of Molecular Diagnostics, 2017, 19, 722-732.	1.2	37
47	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 2017, 26, 17-24.	2.7	24
48	EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC $\hat{a} \in \text{``Experience}$ from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®). Pathology Research and Practice, 2017, 213, 1530-1535.	1.0	12
49	Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions. Annals of Hematology, 2017, 96, 1493-1500.	0.8	15
50	Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leukemia and Lymphoma, 2017, 58, 633-638.	0.6	24
51	<i>hsa-mir-183</i> is frequently methylated and related to poor survival in human hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 1568.	1.4	17
52	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	0.6	0
53	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell, 2016, 30, 75-91.	7.7	144
54	Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathology Research and Practice, 2016, 212, 583-597.	1.0	109

#	Article	IF	CITATIONS
55	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. Medical Oncology, 2016, 33, 59.	1.2	22
56	Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensusâ€based study. Histopathology, 2016, 68, 905-915.	1.6	67
57	Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 191-201.	1.4	12
58	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 697-705.	1.4	24
59	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. Journal of Clinical Oncology, 2016, 34, 2341-2349.	0.8	246
60	Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 644-650.	2.0	10
61	Precise <i>ERBB2</i> copy number assessment in breast cancer by means of molecular inversion probe array analysis. Oncotarget, 2016, 7, 82733-82740.	0.8	11
62	Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget, 2016, 7, 30084-30093.	0.8	42
63	MicroRNA expression profiles in BCR-ABL-negative primary myelofibrosis with chromosome 7q defects. Journal of Hematopathology, 2015, 8, 203-208.	0.2	2
64	A child with Li–Fraumeni syndrome: Modes to inactivate the second allele of <i>TP53</i> in three different malignancies. Pediatric Blood and Cancer, 2015, 62, 1481-1484.	0.8	22
65	Aberrant expression of caspase 14 in salivary gland carcinomas. Journal of Oral Pathology and Medicine, 2015, 44, 444-448.	1.4	2
66	Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival. Clinical Epigenetics, 2015, 7, 110.	1.8	14
67	Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation. Transplant International, 2015, 28, 1299-1307.	0.8	18
68	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. PLoS ONE, 2015, 10, e0136845.	1.1	30
69	Correlating 3D morphology with molecular pathology: fibrotic remodelling in human lung biopsies. Thorax, 2015, 70, 1197-1198.	2.7	9
70	Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction. American Journal of Pathology, 2015, 185, 3178-3188.	1.9	35
71	The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. Human Pathology, 2015, 46, 1341-1349.	1.1	41
72	Expression of Toll-Like Receptors in Chronic Histiocytic Intervillositis of the Placenta. Fetal and Pediatric Pathology, 2015, 34, 407-412.	0.4	15

#	Article	IF	CITATIONS
73	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. Leukemia Research, 2015, 39, 1292-1298.	0.4	15
74	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine, 2015, 7, 315ra188.	5.8	261
75	Hodgkin's Disease / Hodgkin-PTLD after Solid Organ Transplantation in Children: A Report on 16 Patients Treated According to Subsequent Gpoh-HD Treatment Schedules. Blood, 2014, 124, 1612-1612.	0.6	1
76	Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial. Blood, 2014, 124, 4468-4468.	0.6	24
77	The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT. Blood, 2013, 122, 2078-2078.	0.6	1
78	Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome. Blood, 2013, 122, 2781-2781.	0.6	0
79	Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study. Blood, 2013, 122, 2822-2822.	0.6	0
80	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. Gastroenterology, 2012, 143, 811-820.e15.	0.6	178
81	Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer. Disease Markers, 2012, 32, 337-342.	0.6	5
82	Myelofibrosis: molecular and cell biological aspects. Fibrogenesis and Tissue Repair, 2012, 5, S21.	3.4	19
83	Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy Blood, 2012, 120, 2826-2826.	0.6	11
84	Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q). Blood, 2012, 120, 522-522.	0.6	0
85	Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364) Blood, 2012, 120, 2840-2840.	0.6	0
86	Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 283-289.	1.4	69
87	Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. Journal of Hematopathology, 2011, 4, 61-68.	0.2	17
88	The Phenotype of Human STK4 Deficiency. Blood, 2011, 118, 692-692.	0.6	2
89	Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,. Blood, 2011, 118, 3819-3819.	0.6	0
90	Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1761-1761.	0.6	0

#	Article	IF	CITATIONS
91	G6PC3 Deficiency Associated with Congenital Neutropenia and Enterocolitis. Blood, 2011, 118, 2170-2170.	0.6	2
92	Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases. Blood, 2011, 118, 4514-4514.	0.6	0
93	Aberrant proplatelet formation in chronic myeloproliferative neoplasms. Leukemia Research, 2010, 34, 1424-1429.	0.4	17
94	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget, 2010, 1, 483-496.	0.8	52
95	New G-CSF-Dependent Signaling Pathway and Its Role In Patients with Severe Congenital Neutropenia and Acute Myeloid Leukemia. Blood, 2010, 116, 385-385.	0.6	0
96	Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q. Blood, 2010, 116, 30-30.	0.6	0
97	Cytokeratin RNA amplification as a molecular method for the detection of lymph node metastases in breast cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 93-94.	1.4	0
98	Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression Blood, 2009, 114, 3818-3818.	0.6	0
99	Severe Early-Onset Inflammatory Bowel Disease Caused by IL10 Receptor Deficiency Can Be Cured by Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 713-713.	0.6	0
100	Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 537-543.	1.4	53
101	Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML Blood, 2008, 112, 1647-1647.	0.6	5
102	Ectopic Expression of the Extracellular Domain of Mpl Is Sufficient to Induce a Hematopoietic Population Crisis. Blood, 2008, 112, 2886-2886.	0.6	4
103	Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Modern Pathology, 2007, 20, 864-870.	2.9	135
104	Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd \hat{I}_{q} -associated protein (ZAP-70). Human Pathology, 2006, 37, 1153-1161.	1.1	24
105	Myeloablative Conditioning of Patients with Myelofibrosis with Myeloid Metaplasia Using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT) with High Doses of CD34+ Cells Results in Hematologic Responses - 32 Months Follow-Up of Three Patients and Short-Term Results of a New Study Blood. 2005, 106, 5515-5515.	0.6	0
106	Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transplant International, 2004, 17, 293-300.	0.8	17
107	Cell cycle and no end. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 313-323.	1.4	24
108	Increased Chimerism of Bronchial and Alveolar Epithelium in Human Lung Allografts Undergoing Chronic Injury. American Journal of Pathology, 2003, 162, 1487-1494.	1.9	176

#	Article	IF	CITATIONS
109	Detection of chromosomal imbalances in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2002, 2, 120-128.	1.5	3
110	Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. Journal of Pathology, 2002, 198, 292-299.	2.1	183
111	High frequency of epithelial chimerism in liver transplants demonstrated by microdissection and STR-analysis. Hepatology, 2002, 35, 110-116.	3.6	107
112	Correlation of MRI and CT findings with histopathology in hepatic angiomyolipoma. European Radiology, 2001, 11, 1389-1395.	2.3	62
113	Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness. Laboratory Investigation, 2001, 81, 565-571.	1.7	35
114	Quantitative Analysis of Promoter Hypermethylation in Laser-Microdissected Archival Specimens. Laboratory Investigation, 2001, 81, 635-637.	1.7	45
115	Cytogenetic Aberrations in Primary and Recurrent Fibrolamellar Hepatocellular Carcinoma Detected by Comparative Genomic Hybridization. American Journal of Clinical Pathology, 2000, 114, 867-874.	0.4	50